Latest News by Industry
- Acquired Intelligent Fingerprinting Limited and its proprietary drugs of abuse screening technology -
- Announced new additions to Board of Directors and name change to Intelligent Bio Solutions Inc. -
- Company to host conference call & webcast today at 4:30 p.m. ET -
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced its preliminary financial results for the first financial quarter ended September 30, 2022 and provided a business update. Management will host a webcast and conference call at 4:30 p.m. ET today.
“As reflected in our name change to Intelligent Bio Solutions, this last quarter represents a sea change in the growth and evolution of the Company with the highly synergistic acquisition of Intelligent Fingerprinting Limited (“IFP”) with its proprietary and already well-established technology for on-site drugs of abuse testing,” stated Harry Simeonidis as Chief Executive Officer of Intelligent Bio Solutions. “Combining the two businesses presents an exceptional opportunity to benefit from each other’s unique expertise and functional strengths. IFP brings a proven ability to commercialize and grow novel diagnostic products, which fits exceptionally well with our extensive regulatory experience. Similarly, IFP’s successful establishment of a manufacturing facility in the UK will be invaluable as we ramp up operations at our new facility in Newcastle, Australia. R&D teams are already integrating and exploring the depth and breadth of saliva- and sweat-based testing for a broad array of potential additional test substrates, including hormones, infectious diseases, oncology, and fertility among others.”
First Quarter Highlights, Recent Operational Developments
Strategic Partnerships & Pipeline Development
Business Development
Commercial Development
Governance
Anticipated Events and Targeted Milestones for the Coming Fiscal Year
First Quarter Ended September 30, 2022, Financial Results
As of September 30, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $5.74 million, compared to approximately $8.24 million on June 30, 2022.
The major components of outflows were expenditure relating to the proposed pilot manufacturing facility in Newcastle, reduction in current liabilities from June 2022, exchange rate losses from conversion of foreign currency balances to USD, and general overhead.
For the quarter ended, September 30, 2022, the Company had a preliminary net loss of $1.21 million or $0.08 per share compared to a net loss of $1.43 million or $0.10 per share for same period the prior year. This decrease in loss is primarily due to more government support income recognised on the current period compared to same period the prior year.
Government support income was $0.31 million compared to $0.00 for the quarter ended September 30, 2022 and 2021 respectively. This is the result of increased qualifying expenditure incurred in setting up of the pilot manufacturing facility.
The Company is of the view that based on the current operating plan and financial resources, its cash, cash equivalents and marketable securities as of September 30, 2022, will be sufficient to cover expenses and capital requirements into the first half of calendar year 2023. This cash runway forecast does not incorporate revenue from planned new markets for the IFP product, nor the potential exercise of the glucose North American license option agreement.
Webcast Information:
| Title: | Intelligent Bio Solutions Inc. First Quarter 2023 Financial Results Conference Call & Webcast | ||
| Date: | Wednesday, November 9, 2022 | ||
| Time: | 4:30 p.m. ET | ||
| Conference Call Details: | Toll-Free: 1-877-300-8521 International: 1-412-317-6026 Conference ID: 10172375 | ||
| The conference call will be webcast live from the Company’s website and will be available via the following links: | |||
| Webcast: | Webcast Registration Link https://investors.gbs.inc/news-and-events/investor-calendar | ||
The webcast should be accessed 15 minutes prior to the conference call start time.
A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the IR section of the Company’s website.
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to consummate the proposed transaction described in this press release, develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. is a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions to customers globally. With its world-first Biosensor Platform, Intelligent Bio Solutions is developing and launching diagnostic tests urgently needed to help people living with chronic disease. In addition, through its recent acquisition of Intelligent Fingerprinting, the company is the world leader in the advancement of portable drugs of abuse testing through the analysis of fingerprint sweat. The system is a platform technology with potential applications in many areas of diagnostics, and its advantages include being non-invasive, hygienic, fast, and cost-effective. The top selling product screens for recent use of the most commonly taken drugs in workplace settings; opioids, cocaine, methamphetamine, and marijuana. Sample collection takes just seconds, with results in ten minutes. Customers include employers in safety-critical industries such as construction, transport and logistics firms, drug treatment organizations, as well as UK coroners. A laboratory confirmation service is also available.
Company Contact:
Alex Arzeno – Vice President of IR & Communications
Intelligent Bio Solutions Inc.
Investor.Relations@gbs.inc
Media Contact:
Cheryl Billson
Comma Communications
cheryl.billson@commacomms.com
INTELLIGENT BIO SOLUTIONS INC.
PRELIMINARY CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(Amounts in $)
| Three Months Ended September 30, | ||||||||
| 2022 | 2021 | |||||||
| Revenue: | ||||||||
| Other income: | ||||||||
| Government support income | $ | 311,320 | $ | - | ||||
| Total revenue and other income | 311,320 | - | ||||||
| Operating expenses: | ||||||||
| General and administrative expenses | 1,450,418 | 1,332,520 | ||||||
| Development and regulatory approval expenses | 79,274 | 106,799 | ||||||
| Total operating expenses | 1,529,692 | 1,439,319 | ||||||
| Loss from operations | (1,218,372 | ) | (1,439,319 | ) | ||||
| Other income (expense): | ||||||||
| Interest expense | (1,065 | ) | - | |||||
| Realized foreign exchange loss | (2,247 | ) | (3,118 | ) | ||||
| Interest income | 7,606 | 4,597 | ||||||
| Total other income (expense) | 4,294 | 1,479 | ||||||
| Net loss | (1,214,078 | ) | (1,437,840 | ) | ||||
| Net loss attributable to non-controlling interest | (5,785 | ) | (5,188 | ) | ||||
| Net loss attributable to IBS Inc. | $ | (1,208,293 | ) | $ | (1,432,652 | ) | ||
| Other comprehensive loss, net of tax: | ||||||||
| Foreign currency translation loss | $ | (135,559 | ) | $ | (67,482 | ) | ||
| Total other comprehensive loss | (135,559 | ) | (67,482 | ) | ||||
| Comprehensive loss | (1,349,637 | ) | (1,505,322 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | (5,785 | ) | (5,188 | ) | ||||
| Comprehensive loss attributable to IBS Inc. | $ | (1,343,852 | ) | $ | (1,500,134 | ) | ||
| Net loss per share, basic and diluted | $ | (0.08 | ) | $ | (0.10 | ) | ||
| Weighted average shares outstanding, basic and diluted | 14,889,904 | 14,006,127 | ||||||
INTELLIGENT BIO SOLUTIONS INC.
PRELIMINARY CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Amounts in $)
| September 30, 2022 | June 30, 2022 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,742,626 | $ | 8,238,301 | ||||
| Deferred charges | 300,000 | - | ||||||
| Grant receivable, current portion | 1,443,939 | 1,529,882 | ||||||
| Research and development tax incentive receivable | 571,860 | 353,048 | ||||||
| Other current assets | 148,927 | 746,761 | ||||||
| Total current assets | 8,207,352 | 10,867,992 | ||||||
| Long-term grant receivable | 1,031,384 | 1,092,773 | ||||||
| Construction in progress | 416,029 | 391,408 | ||||||
| Other non-current assets | 504,938 | - | ||||||
| TOTAL ASSETS | $ | 10,159,703 | $ | 12,352,173 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 1,038,545 | $ | 1,625,089 | ||||
| Current portion of deferred grant income | 1,018,918 | 2,836,582 | ||||||
| Current employee benefit liabilities | 299,686 | 201,332 | ||||||
| Total current liabilities | 2,357,149 | 4,663,003 | ||||||
| Employee benefit liabilities | 20,791 | 50,626 | ||||||
| Long-term deferred grant income | 2,585,629 | 1,092,773 | ||||||
| Total liabilities | 4,963,569 | 5,806,402 | ||||||
| Commitments and contingencies | ||||||||
| Shareholders' equity: | ||||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 14,889,904 shares issued and outstanding at September 30, 2022 and June 30, 2022, respectively | 148,899 | 148,899 | ||||||
| Additional paid-in capital | 38,440,011 | 38,440,011 | ||||||
| Accumulated deficit | (32,384,146 | ) | (31,175,853 | ) | ||||
| Accumulated other comprehensive loss | (923,694 | ) | (788,135 | ) | ||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 5,281,070 | 6,624,922 | ||||||
| Non-controlling interest | (84,936 | ) | (79,151 | ) | ||||
| Total shareholders' equity | 5,196,134 | 6,545,771 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 10,159,703 | $ | 12,352,173 | ||||